References
- Allsup D J, Cawley J C. The diagnosis and treatment of hairy-cell leukaemia. Blood Rev 2002; 16: 255–262
- Basso K, Liso A, Tiacci E, Benedetti R, Pulsoni A, Foa R, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 2004; 199: 59–68
- Allsup D J, Cawley J C. Diagnosis, biology and treatment of hairy-cell leukaemia. Clin Exp Med 2004; 4: 132–138
- Burthem J, Zuzel M, Cawley J C. What is the nature of the hairy cell and why should we be interested?. Br J Haematol 1997; 97: 511–514
- Zuzel M, Cawley J C. The biology of hairy cells. Best Pract Res Clin Haematol 2003; 16: 1–13
- Lower E E, Franco R S, Martelo O J. Increased tyrosine protein kinase activity in hairy cell and monocytic leukemias. Am J Med Sci 1992; 303: 387–391
- Zhang X, Machii T, Matsumura I, Ezoe S, Kawasaki A, Tanaka H, et al. Constitutively activated Rho guanosine triphosphatases regulate the growth and morphology of hairy cell leukemia cells. Int J Hematol 2003; 77: 263–273
- Kamiguti A S, Harris R J, Slupsky J R, Baker P K, Cawley J C, Zuzel M. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways. Oncogene 2003; 22: 2272–2284
- Neel B G, Gu H, Pao L. The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003; 28: 284–293
- Quesada J R, Reuben J, Manning J T, Hersh E M, Gutterman J U. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310: 15–18
- Du Z, Shen Y, Yang W, Mecklenbrauker I, Neel B G, Ivashkiv L B. Inhibition of IFN-alpha signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway. Proc Natl Acad Sci USA 2005; 102: 10267–10272
- Yi T, Pathak M K, Lindner D J, Ketterer M E, Farver C, Borden E C. Anticancer activity of sodium stibogluconate in synergy with IFNs. J Immunol 2002; 169: 5978–5985
- Pettitt A R, Moran E C, Cawley J C. Homotypic interactions protect chronic lymphocytic leukaemia cells from spontaneous death in vitro. Leuk Res 2001; 25: 1003–1012
- Ormerod M G. The study of apoptotic cells by flow cytometry. Leukemia 1998; 12: 1013–1025
- Lin K, Sherrington P D, Dennis M, Matrai Z, Cawley J C, Pettitt A R. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002; 100: 1404–1409
- Posner B I, Faure R, Burgess J W, Bevan A P, Lachance D, Zhang-Sun G, et al. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 1994; 269: 4596–4604
- Bevan A P, Drake P G, Yale J F, Shaver A, Posner B I. Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis. Mol Cell Biochem 1995; 153: 49–58
- Xu R, Yu Y, Zheng S, Zhao X, Dong Q, He Z, et al. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood 2005; 106: 3142–3149
- Baker P K, Pettitt A R, Slupsky J R, Chen H J, Glenn M A, Zuzel M, et al. Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood 2002; 100: 647–653
- Watson R B, Galvani D W, Nash J R, Cawley J C. Gamma IFN receptor expression in haemic malignancies. Leuk Res 1990; 14: 657–660
- Faltynek C R, Princler G L, Rossio J L, Ruscetti F W, Maluish A E, Abrams P G, et al. Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. Blood 1986; 67: 1077–1082
- Kamiguti A S, Serrander L, Lin K, Harris R J, Cawley J C, Allsup D J, et al. Expression and activity of NOX5 in the circulating malignant B cells of hairy cell leukemia. J Immunol 2005; 175: 8424–8430
- Zhang J, Somani A K, Siminovitch K A. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol 2000; 12: 361–378
- Tamir I, Dal Porto J M, Cambier J C. Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction. Curr Opin Immunol 2000; 12: 307–315
- Quesada J R, Hersh E M, Gutterman J U. Biologic therapy of hairy cell leukemia. Semin Oncol 1984; 11(4 Suppl 2)507–510
- Platanias L C, Fish E N. Signaling pathways activated by interferons. Exp Hematol 1999; 27: 1583–1592
- Saydam G, Aydin H H, Sahin F, Selvi N, Oktem G, Terzioglu E, et al. Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells. Leuk Res 2003; 27: 709–717
- Decatris M. Santhanam S, O'Byrne K. Potential of interferon-alpha in solid tumours: part 1. BioDrugs 2002; 16: 261–281
- Nguyen M H, Wright T L. Therapeutic advances in the management of hepatitis B and hepatitis C. Curr Opin Infect Dis 2001; 14: 593–601